Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas
- PMID: 16397024
- DOI: 10.1158/1078-0432.CCR-05-0976
Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas
Abstract
Purpose: Recent reports revealed that the kinase domain of the ERBB2 gene is somatically mutated in lung adenocarcinoma, suggesting the mutated ERBB2 gene as an oncogene in human cancers. However, because previous reports focused the mutational search of ERBB2 primarily on lung cancers, the data on ERBB2 mutations in other types of human cancers have been largely unknown.
Experimental design: Here, we did a mutational analysis of the ERBB2 kinase domain by PCR single-strand conformational polymorphism assay in gastric, colorectal, and breast carcinoma tissues.
Results: We detected the ERBB2 kinase domain mutations in 9 of 180 gastric carcinomas (5.0%), in 3 of 104 colorectal carcinomas (2.9%), and in 4 of 94 breast carcinomas (4.3%). All of the detected ERBB2 mutations except for one in-frame deletion mutation were missense mutations. Of the 16 ERBB2 mutations detected, 4 affected Val777 in the exon 20 site, and 3 affected Leu755 in the exon 19 site. We simultaneously analyzed the somatic mutations of EGFR, K-RAS, PIK3CA, and BRAF genes in the 16 samples with ERBB2 mutations, and found that all of the 3 colorectal carcinoma samples with ERBB2 mutations harbored K-RAS mutations.
Conclusion: This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.
Similar articles
-
ERBB2 kinase domain mutation in the lung squamous cell carcinoma.Cancer Lett. 2006 Jun 8;237(1):89-94. doi: 10.1016/j.canlet.2005.05.026. Epub 2005 Jul 18. Cancer Lett. 2006. PMID: 16029927
-
Somatic mutations of the ERBB4 kinase domain in human cancers.Int J Cancer. 2006 Mar 15;118(6):1426-9. doi: 10.1002/ijc.21507. Int J Cancer. 2006. PMID: 16187281
-
ERBB2 kinase domain mutation in a gastric cancer metastasis.APMIS. 2005 Oct;113(10):683-7. doi: 10.1111/j.1600-0463.2005.apm_284.x. APMIS. 2005. PMID: 16309427
-
K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review.Cancer Detect Prev. 2000;24(1):1-12. Cancer Detect Prev. 2000. PMID: 10757118 Review.
-
High-throughput mutational analysis of the human cancer genome.Pharmacogenomics. 2006 Jun;7(4):597-612. doi: 10.2217/14622416.7.4.597. Pharmacogenomics. 2006. PMID: 16753007 Review.
Cited by
-
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.Crit Rev Oncog. 2012;17(1):1-16. doi: 10.1615/critrevoncog.v17.i1.20. Crit Rev Oncog. 2012. PMID: 22471661 Free PMC article. Review.
-
Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.Oncogene. 2010 Jun 10;29(23):3335-48. doi: 10.1038/onc.2010.112. Epub 2010 Apr 12. Oncogene. 2010. PMID: 20383197 Free PMC article.
-
The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy.J Signal Transduct. 2011;2011:804236. doi: 10.1155/2011/804236. Epub 2011 Feb 24. J Signal Transduct. 2011. PMID: 21637380 Free PMC article.
-
SORLA regulates endosomal trafficking and oncogenic fitness of HER2.Nat Commun. 2019 May 28;10(1):2340. doi: 10.1038/s41467-019-10275-0. Nat Commun. 2019. PMID: 31138794 Free PMC article.
-
Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.PLoS One. 2018 Feb 1;13(2):e0190942. doi: 10.1371/journal.pone.0190942. eCollection 2018. PLoS One. 2018. PMID: 29389942 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous